BACKGROUND: Accumulating evidence suggests that fetal exposure to maternal psychiatric symptoms is associated with future risk for psychopathology. One potential pathway is distress-linked constriction in uterine or umbilical blood flow (UBF). With approximately 6.6% of pregnant women taking an antidepressant, an ecologically valid investigation of this hypothesis must consider the potential concomitant influence of pharmacotherapy on UBF. METHODS: Pregnant women (n = 101) with lifetime histories of mental illness were evaluated every 4 to 6 weeks during gestation for mood symptoms and medication use; women underwent an ultrasound examination for UBF at approximately 25 weeks gestation. RESULTS: No associations were observed between UBF and three assessments of maternal prenatal depression and anxiety (acute: coincident with the UBF scan; proximal: within 2 weeks of the scan; chronic: serial symptom ratings). Chronic and acute use of bupropion was associated with reduced UBF, even after controlling for pregnancy complications. Chronic use of atypical antipsychotics also was associated with decreased UBF. There were no associations between serotonergic antidepressant use and UBF. CONCLUSIONS: Contrary to a popular hypothesis, depression and anxiety-associated reductions in UBF may not be a pathway by which risk is conferred during prenatal development. However, while requiring replication, our findings suggest that prenatal bupropion exposure may be associated with reductions in UBF.
BACKGROUND: Accumulating evidence suggests that fetal exposure to maternal psychiatric symptoms is associated with future risk for psychopathology. One potential pathway is distress-linked constriction in uterine or umbilical blood flow (UBF). With approximately 6.6% of pregnant women taking an antidepressant, an ecologically valid investigation of this hypothesis must consider the potential concomitant influence of pharmacotherapy on UBF. METHODS: Pregnant women (n = 101) with lifetime histories of mental illness were evaluated every 4 to 6 weeks during gestation for mood symptoms and medication use; women underwent an ultrasound examination for UBF at approximately 25 weeks gestation. RESULTS: No associations were observed between UBF and three assessments of maternal prenatal depression and anxiety (acute: coincident with the UBF scan; proximal: within 2 weeks of the scan; chronic: serial symptom ratings). Chronic and acute use of bupropion was associated with reduced UBF, even after controlling for pregnancy complications. Chronic use of atypical antipsychotics also was associated with decreased UBF. There were no associations between serotonergic antidepressant use and UBF. CONCLUSIONS: Contrary to a popular hypothesis, depression and anxiety-associated reductions in UBF may not be a pathway by which risk is conferred during prenatal development. However, while requiring replication, our findings suggest that prenatal bupropion exposure may be associated with reductions in UBF.
Authors: Colleen Doyle; Elizabeth Werner; Tianshu Feng; Seonjoo Lee; Margaret Altemus; Joseph R Isler; Catherine Monk Journal: Dev Psychobiol Date: 2015-05-06 Impact factor: 3.038
Authors: Georgios Schoretsanitis; Sara V Carlini; Majnu John; John M Kane; Kristina M Deligiannidis Journal: J Clin Psychopharmacol Date: 2021 Sep-Oct 01 Impact factor: 3.153
Authors: Kristin Palmsten; Krista F Huybrechts; Karin B Michels; Paige L Williams; Helen Mogun; Soko Setoguchi; Sonia Hernández-Díaz Journal: Epidemiology Date: 2013-09 Impact factor: 4.822
Authors: Terri A Levine; Ruth E Grunau; Ricardo Segurado; Sean Daly; Michael P Geary; Mairead M Kennelly; Keelin O'Donoghue; Alyson Hunter; John J Morrison; Gerard Burke; Patrick Dicker; Elizabeth C Tully; Fergal D Malone; Fiona A Alderdice; Fionnuala M McAuliffe Journal: BMJ Open Date: 2017-06-21 Impact factor: 2.692
Authors: Elizabeth C Braithwaite; Susannah E Murphy; Paul G Ramchandani; Jonathan Hill Journal: Psychoneuroendocrinology Date: 2017-09-05 Impact factor: 4.905